Tag Archives: CRECF

Top Stocks To Buy Right Now

Source: Stock Photo

Although it’s not a certainty yet, BP (NYSE:BP) says it is seriously considering spinning off its pipeline assets into an MLP. It will probably be called BP Midstream Partners, and would include its Gulf Coast and Midwest pipeline assets.

According to BP, an IPO would provide the company “the opportunity to grow its pipeline business, while also giving investors new venues to find value.”

There are several things to consider in regard to this announcement, including the impetus behind the idea, how it will impact BP’s performance and share price, and the way it views its other businesses.

Top Stocks To Buy Right Now: Telephone and Data Systems, Inc.(TDS)

Advisors’ Opinion:

  • [By Monica Gerson]

    Telephone & Data Systems, Inc. (NYSE: TDS) is projected to report its quarterly earnings at $0.10 per share on revenue of $1.26 billion.

    PharMerica Corporation (NYSE: PMC) is estimated to report its quarterly earnings at $0.43 per share on revenue of $509.45 million.

Top Stocks To Buy Right Now: DBV Technologies S.A.(DBVT)

Advisors’ Opinion:

  • [By Lisa Levin]

    DBV Technologies SA – ADR (NASDAQ: DBVT) shares dropped 46 percent to $26.11 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.

  • [By Monica Gerson]

    DBV Technologies SA ADR (NASDAQ: DBVT) is expected to post a quarterly loss at $0.60 per share.

    Northern Technologies International Corp (NASDAQ: NTIC) is projected to post its quarterly earnings.

  • [By Paul Ausick]

    DBV Technologies SA (NASDAQ: DBVT) dropped about 53.5% Monday to post a new 52-week low of $22.33 after closing at $48.07 on Friday. The stock’s 52-week high is $50.57. Volume of around 12 million was about 60 times the daily average. The French drug maker’s peanut allergy treatment failed a phase 3 study.

Top Stocks To Buy Right Now: Infinity Pharmaceuticals, Inc.(INFI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, healthcare shares fell by 0.98 percent. Meanwhile, top losers in the sector included Cleveland BioLabs, Inc. (NASDAQ: CBLI), down 25 percent, and Infinity Pharmaceuticals Inc. (NASDAQ: INFI), down 8 percent.

  • [By Lisa Levin]

    Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares dropped 70 percent to $1.32. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint.

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell 0.32 percent. Meanwhile, top losers in the sector included Antares Pharma Inc (NASDAQ: ATRS), down 38 percent, and Infinity Pharmaceuticals Inc. (NASDAQ: INFI) down 16 percent.

Top Stocks To Buy Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

Top Stocks To Buy Right Now: Critical Elements Corporation (CRECF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    ILC reminds me of Critical Elements [TSXV:CRE] (OTCQX:CRECF) having five projects (CRE has 11), and also of Galaxy Resources (ASX:GXY) (OTCPK:GALXF) by being diversified across brine and spodumene and across three continents. Also some similarity with Neo Lithium’s (OTC:NTTHF) [TSXV:NLC] early stage Argentinean brine project which I recently wrote about here. However, ILC trades at a much smaller market cap of US$8m to that of Critical Elements (US$85m) or Galaxy Resources (US$724m). This is partly due to ILC giving away significant percentages of their projects, and because they are still in the early stages of development.

Best Medical Stocks To Watch For 2018

No good deed goes unpunished, as the saying goes. On first impression, that’s what happened to Dr. Robert McClendon, a Texas physician. He lent $100,000 to a business to cover its payroll. And then he got hit with a $4.3 million IRS penalty for the company’s payroll taxes, a penalty that was just upheld in court. But, as often happens with taxes, the situation is more complex. The business was Dr. McClendon’s, and sadly, one of his employees embezzled the payroll tax money.

The court concluded that Dr. McClendon was responsible, and acted willfully. You can be ‘willful’ under the tax law even if you didn’t have a bad motive or evil intent. Dr. McClendon was the owner of Family Practice, a medical services provider. Family Practice hired Richard Stephen as its CFO. By 2009, Family Practice owed over $10 million in unpaid payroll and other withholding taxes. Dr. McClendon learned that the taxes were unpaid on May 11, 2009. Mr. Stephen plead guilty to three counts of felony theft of money that he embezzled.

Best Medical Stocks To Watch For 2018: EP Energy Corporation(EPE)

Advisors’ Opinion:

  • [By Andrew Efimoff]

    WTI crude oil plunged 3.11 percent on Friday to $48.99 a barrel. Below are the biggest energy losers for the day:

    California Resources Corporation (NYSE: CRC): -19.22%
    Dynamic Materials (NASDAQ: BOOM): -12.39%
    Clayton Williams Energy (NYSE: CWEI): -11.45%
    Dynergy (NYSE: DYN): -11.91%
    EP Energy Corporation (NYSE: EPE): -11.20%
    Mexco Energy (NYSE: MXC) -10.90%
    Whiting Petroleum (NYSE: WLL) -10.79%
    Southwestern Energy Company (NYSE: SWN) -10.79%
    SM Energy Company (NYSE: SM) -10.38%
    Real Goods Solar (NASDAQ: RGSE) -10.34%

    Posted-In: Commodities After-Hours Center Markets Movers

  • [By Paul Ausick]

    EP Energy Corp. (NYSE: EPE) posted a new 52-week low of $1.85 Tuesday, down nearly 22% after closing at $2.37 on Monday. The 52-week high is $7.49. Volume was about 3.2 million, around 5 times the daily average of around 600,000. The oil and gas exploration and production firm has launched an exchange program extending the maturity date to 2024 on $1.2 billion in 9.375% notes due in 2020.

Best Medical Stocks To Watch For 2018: Benchmark Electronics, Inc.(BHE)

Advisors’ Opinion:

  • [By Anders Bylund]

    How do you pick the top names in this broadly lucrative industry? I’m here to show you my three favorites in the printed circuit board market: Sanmina (NASDAQ:SANM), Benchmark Electronics (NYSE:BHE), and TTM Technologies (NASDAQ:TTMI), each one tailor-made for a different type of investor.

Best Medical Stocks To Watch For 2018: Critical Elements Corporation (CRECF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    ILC reminds me of Critical Elements [TSXV:CRE] (OTCQX:CRECF) having five projects (CRE has 11), and also of Galaxy Resources (ASX:GXY) (OTCPK:GALXF) by being diversified across brine and spodumene and across three continents. Also some similarity with Neo Lithium’s (OTC:NTTHF) [TSXV:NLC] early stage Argentinean brine project which I recently wrote about here. However, ILC trades at a much smaller market cap of US$8m to that of Critical Elements (US$85m) or Galaxy Resources (US$724m). This is partly due to ILC giving away significant percentages of their projects, and because they are still in the early stages of development.

Best Medical Stocks To Watch For 2018: Marvell Technology Group Ltd.(MRVL)

Advisors’ Opinion:

  • [By Peter Graham]

    Mid cap fabless semiconductor stock Marvell Technology Group Ltd (NASDAQ: MRVL) reported fiscal Q1 2018 earnings after the Thursday market close that beat expectations. Net revenue was $579.180 million versus $519.383 million andnet income was $96.970 million versus a net loss of $13.271 million. The CEO commented:

  • [By Chris Lange]

    When Marvell Technology Group Ltd. (NASDAQ: MRVL) released its fiscal third-quarter results after the markets closed on Tuesday, it posted $0.34 in earnings per share (EPS) and $616.3 million in revenue. Consensus estimates had called for $0.33 in EPS on revenue of $613.1 million. The same period of last year reportedly had EPS of $0.21 and $604.75 million in revenue.

  • [By Lisa Levin]

    Marvell Technology Group Ltd. (NASDAQ: MRVL) shares shot up 10 percent to $14.70 after the company reported upbeat Q3 results and announced a $1 billion share buyback.

Best Medical Stocks To Watch For 2018: Sonoco Products Company(SON)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Deutsche Bank’s Debbie Jones and team contend that Sonoco’s (SON) sale of its plastic-container business to Australia’s Amcor is a sign that M&A is in the offing. They explain why:

    Sonoco announced (9/1) that it is selling its Rigid Plastics Blow Molding operations to Amcor (AMC.AU) for $280M. The transaction price represents a multiple of ~8.0x LTM EBITDA. The business had annual sales of ~$210M and consisted of six production sites in the US and one in Canada. Blow molding operations represented ~10% of Sonocos Consumer Packaging segment sales and EBITDA. The transaction is expected to close in Q4. We expect the proceeds to be used to for M&A focused in flexible packaging, thermoforming and temperature-assured packaging.

    We dont believe Sonoco considered its blow molding operations essential to its growth strategy. This standalone business is also more capital intensive compared to some of its other plastic packaging businesses and SON held a small position in the overall market. Ultimately, the company decided it wants to focus its capital in higher growth platforms. We do not expect the divestment to reduce resin buying scale for Sonoco’s remaining assets given different resin buying. Note that with the divestiture of blow molding and the Canton closures plant (divested in Feb. 2015), this makes the ~$100M reels business the last standalone business in the portfolio, but we do not expect this to be divested in the near-term unless cash is needed for much larger M&A.

    Shares of Sonoco have gained 1.3% to $52.49 at 2:12 p.m. today.

     

Best Medical Stocks To Watch For 2018: Scana Corporation(SCG)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and SCANA Corporation (NYSE: SCG) down 1 percent.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was SCANA Corp. (NYSE: SCG) which traded down over 6% at $42.38. The stocks 52-week range is $41.15 to $74.99. Volume was over 3.5 million versus the daily average of 2.2 million shares.

  • [By Lisa Levin]

    In trading on Friday, utilities shares were relative laggards, down on the day by about 0.32 percent. Meanwhile, top losers in the sector included Genie Energy Ltd (NYSE: GNE), down 3 percent, and SCANA Corporation (NYSE: SCG), down 3 percent.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was SCANA Corp. (NYSE: SCG) which rose over 22% to $47.71. The stocks 52-week range is $37.10 to $73.81. Volume was about 19 million compared to its average volume of 2 million.

otc stocks

More details emerged about the proposed initial public offering (IPO) of shares in the world’s largest company, the state oil giant Saudi Aramco, following comments Saudi oil ministry advisor Ibrahim Muhanna made to the Wall Street Journal. The company will likely float around 5% of its shares, Muhanna said, and the listing may come within the next year.

Company History

Saudi Aramco, officially the Saudi Arabian Oil Company, began as a Saudi-American joint enterprise in the 1930s. The Saudi government began building up a stake in the 1973, following the Yom Kippur War, and took full control in 1980. The company is the largest in the world by a significant margin, though the exact size is unknown. Reporting Muhanna’s comments, the WSJ cited a “conservative number” of $2.5 trillion, but the paper has put forward a high estimate of $10 trillion in the past. (See also, Saudi Aramco: An IPO for the World’s Largest Firm?)

otc stocks: tronc, Inc. (TRNC)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In a purge fairly unprecedented in American newspapers, Tronc (TRNC) has replaced the senior leadership of the Los Angeles Times. With a single announcement, the company announced both new leadership for the Times’ business side and for its newsroom.

  • [By Lee Jackson]

    Tronc Inc. (NASDAQ: TRNC) had a gigantic buyer recently. Michael Ferro, who is a director, purchased a stunning 2,500,000 sharesat $15 apiece. The total for the trade was an incredible $37,500,000.Thismultiplatform media and marketing solutions company publishes newspapers in the United States, as well as provides a suite of digital marketing services for local, regional and national marketers. Its shares ended trading on Friday at $13.87.Their 52-week trading range is $8.76 to $17.93, and the Wall Street consensus price target is $21.

otc stocks: CVR Refining, LP(CVRR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CVR Refining LP (NYSE: CVRR) were down 11 percent to $10.00. Velocity Midstream Partners and CVR Refining disclosed the execution of agreements related to the construction of a crude oil pipeline from the SCOOP play in Central Oklahoma to CVR's Wynnewood refinery.

  • [By Tyler Crowe]

    For refiners, though, that spread in price led to very lucrative refining margins. As that spread has narrowed, so too has margins for refiners.

    Refining Margins Q4 2012 Q2 2013
    Valero (NYSE: VLO  ) $12.27 $9.26
    Phillips 66 (NYSE: PSX  ) $13.67 $9.88
    HollyFrontier (NYSE: HFC  ) $24.00 $20.28
    CVR Refining (NYSE: CVRR  ) $28.08 $20.30

    Source: Company Earnings releases

  • [By Robert Rapier]

    CVR Partners’ fertilizer plant is located in Coffeyville, Kansas, adjacent to the refinery owned by CVR Refining (NYSE: CVRR). CVR Energy (NYSE: CVI), majority-owned by Carl Icahn via Icahn Enterprises (NYSE: IEP), is the general partner and owns most of the units for both CVR Partners and CVR Refining.

otc stocks: PrimeEnergy Corporation(PNRG)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, energy shares were relative laggards, down on the day by about 0.18 percent. Meanwhile, top losers in the sector included PrimeEnergy Corporation (NASDAQ: PNRG), down 8 percent, and Aegean Marine Petroleum Network Inc. (NYSE: ANW) down 3 percent.

  • [By Lisa Levin]

    In trading on Monday, energy shares fell 1.03 percent. Meanwhile, top losers in the sector included PrimeEnergy Corporation (NASDAQ: PNRG), down 4 percent, and Carrizo Oil & Gas Inc (NASDAQ: CRZO) down 7 percent.

otc stocks: Critical Elements Corporation (CRECF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    ILC reminds me of Critical Elements [TSXV:CRE] (OTCQX:CRECF) having five projects (CRE has 11), and also of Galaxy Resources (ASX:GXY) (OTCPK:GALXF) by being diversified across brine and spodumene and across three continents. Also some similarity with Neo Lithium’s (OTC:NTTHF) [TSXV:NLC] early stage Argentinean brine project which I recently wrote about here. However, ILC trades at a much smaller market cap of US$8m to that of Critical Elements (US$85m) or Galaxy Resources (US$724m). This is partly due to ILC giving away significant percentages of their projects, and because they are still in the early stages of development.

great stocks to invest in today

Rheumatoid arthritis (RA) is one of the most prominent inflammatory autoimmune diseases in the world and the US, affecting an estimated 4.9 million people globally and 1.3 million Americans. First-line treatment, often a disease-modifying antirheumatic drug (DMARD), is used to reduce symptoms such as inflammation.

However, the focus of this article will be on a different type of drug called biologics. These often act as a second-line treatment when patients have had an inadequate response to DMARDs (around 33% of patients) such as methotrexate (MTX) and are used in conjunction with background DMARDs to increase clinical remission rates. They can and are also used as a first-line treatment, but it depends on the patient and their needs. Biologics have the highest rate of sales growth in RA due to their efficacy, ability to address unmet clinical need, and their pricing. According to Visiongain, 92.3% of global RA sales in 2015 came from biologics.

Additionally, we’ll keep our focus on the US, rather than globally, given that sales from the US exceed those of the other major markets. In most RA biologics, US sales exceed all other major markets combined. In summary, we’ll talk about the current market biologic products, biosimilars and pipeline biologic products in the US.

great stocks to invest in today: Shutterfly Inc.(SFLY)

Advisors’ Opinion:

  • [By Chris Lange]

    When Shutterfly Inc. (NASDAQ: SFLY) released its fourth-quarter earnings report after the markets closed on Wednesday, the company said it had $2.63 in earnings per share (EPS) and $561.2 million in revenue. The consensus estimates had called for $2.84 in EPS and revenue of $586.4 million. In the same period of last year, it posted EPS of $3.57 and $548.1 million in revenue.

great stocks to invest in today: Callon Petroleum Company(CPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

great stocks to invest in today: Critical Elements Corporation (CRECF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    ILC reminds me of Critical Elements [TSXV:CRE] (OTCQX:CRECF) having five projects (CRE has 11), and also of Galaxy Resources (ASX:GXY) (OTCPK:GALXF) by being diversified across brine and spodumene and across three continents. Also some similarity with Neo Lithium’s (OTC:NTTHF) [TSXV:NLC] early stage Argentinean brine project which I recently wrote about here. However, ILC trades at a much smaller market cap of US$8m to that of Critical Elements (US$85m) or Galaxy Resources (US$724m). This is partly due to ILC giving away significant percentages of their projects, and because they are still in the early stages of development.

great stocks to invest in today: AdvanSix Inc. (ASIX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Vodafone Group (VOD) , Schlumberger (SLB) , Encana (ECA) , Arconic (ARNC) and AdvanSix (ASIX) .

    Cramer was bearish on U.S. Silica Holdings (SLCA) .

pick stock

A lot of people develop deep feelings when it comes to the stock market. They get emotionally hooked on stocks, "stories" about companies and even the market’s future.

Most times, this relationship ends badly. Although the market represents the "animal spirits" of millions of investors, it doesn’t single out your feelings. It has no regard for what you think or do.

That’s why it’s always time to be cautious because you need to look at risk. Bull markets don’t last forever and you need to be vigilant. Here are five things the market doesn’t care about:

Shutterstock

— Whether you think it’s high or low. By historical standards, what investors are willing to pay for shares is high. The Shiller P/E Ratio, a benchmark for market valuation, is hovering around 38. It was around 44 during the height of the dot.com bubble and 27 in 2007 (before the credit bubble crash).

pick stock: CSX Corporation(CSX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    CSX (CSX) soared to the top of the S&P 500 today after railroad operator was upgraded by BMO Capital Markets following its big activist-inspired move last week.

    Agence France-Presse/Getty Images

    CSXgained 3.7% to $45.99 today, while the S&P 500 declined 0.3% to 2,265.20.

    BMO’sFadiChamoun andTarunJoshi explain why they upgraded CSX to Outperform from Market Perform:

    We are upgrading CSX shares to Outperform from Market Perform and raising our target price to $55 from $38. We see upside to around $80 over the medium term. Our constructive thesis is predicated on Mantle Ridge LP being successful in its effort to install Hunter Harrison as CEO of CSX. We believe that the probability of this occurring is fairly high without going down the road of a bruising proxy battle.

    CSX’s market capitalization rose to $43.1 billion today from $41.4 billion yesterday. It reported net income of $2 billion on sales of $11.1 billion in 2016.

  • [By Craig Jones]

    Dan Nathan suggested on CNBC's Options Action a bearish trading idea in CSX Corporation (NASDAQ: CSX). He explained that the stock jumped 80 percent from its 52-week low in February and it gained around 20 percent since the election. It has significantly outperformed the Dow Jones Transportation index in that period and Nathan thinks that it is reasonable to expect a pull back.

  • [By Rich Duprey]

    I ran a screen to identify the best-performing stocks from the S&P 500 in January. The top three performers during the month were Alcoa (NYSE:AA), CSX (NASDAQ:CSX), and NRG Energy (NYSE:NRG). Let’s see why they were the big standouts and whether they can keep it going.

pick stock: Critical Elements Corporation (CRECF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    ILC reminds me of Critical Elements [TSXV:CRE] (OTCQX:CRECF) having five projects (CRE has 11), and also of Galaxy Resources (ASX:GXY) (OTCPK:GALXF) by being diversified across brine and spodumene and across three continents. Also some similarity with Neo Lithium’s (OTC:NTTHF) [TSXV:NLC] early stage Argentinean brine project which I recently wrote about here. However, ILC trades at a much smaller market cap of US$8m to that of Critical Elements (US$85m) or Galaxy Resources (US$724m). This is partly due to ILC giving away significant percentages of their projects, and because they are still in the early stages of development.

pick stock: iShares MSCI Japan (EWJ)

Advisors’ Opinion:

  • [By Stephen Leeb, Founder and Research Chairman, Leeb Group]

    Despite the 30% plus gains they’ve enjoyed this year, the stocks that comprise the iShares MSCI Japan ETF (EWJ) still trade at 14 times depressed earnings.

pick stock: (MALRF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

pick stock: CVR Refining, LP(CVRR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CVR Refining LP (NYSE: CVRR) were down 11 percent to $10.00. Velocity Midstream Partners and CVR Refining disclosed the execution of agreements related to the construction of a crude oil pipeline from the SCOOP play in Central Oklahoma to CVR's Wynnewood refinery.

  • [By Tyler Crowe]

    For refiners, though, that spread in price led to very lucrative refining margins. As that spread has narrowed, so too has margins for refiners.

    Refining Margins Q4 2012 Q2 2013
    Valero (NYSE: VLO  ) $12.27 $9.26
    Phillips 66 (NYSE: PSX  ) $13.67 $9.88
    HollyFrontier (NYSE: HFC  ) $24.00 $20.28
    CVR Refining (NYSE: CVRR  ) $28.08 $20.30

    Source: Company Earnings releases

  • [By Robert Rapier]

    CVR Partners’ fertilizer plant is located in Coffeyville, Kansas, adjacent to the refinery owned by CVR Refining (NYSE: CVRR). CVR Energy (NYSE: CVI), majority-owned by Carl Icahn via Icahn Enterprises (NYSE: IEP), is the general partner and owns most of the units for both CVR Partners and CVR Refining.